Current regulatory approaches for accessing potential COVID-19 therapies
This commentary aims to elaborate challenges in the regulatory approaches for accessing and investigating COVID-19 potential therapies either with off-label use, compassionate use, emergency use or for clinical trials. Since no therapies have been formally approved and completely effective and safe...
Saved in:
Main Authors: | Vesa Halimi (Author), Armond Daci (Author), Simona Stojanovska (Author), Irina Panovska-Stavridis (Author), Milena Stevanovic (Author), Venko Filipce (Author), Aleksandra Grozdanova (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2020-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The use of remdesivir outside of clinical trials during the COVID-19 pandemic
by: Vesa Halimi, et al.
Published: (2020) -
Glycoconjugates as target antigens in peripheral neuropathies
by: Ljubica Suturkova, et al.
Published: (2014) -
Can mathematical modelling solve the current Covid-19 crisis?
by: Jasmina Panovska-Griffiths
Published: (2020) -
Biosimilars: Current regulatory perspective and challenges
by: Diwakar Jha, et al.
Published: (2013) -
Regulatory and Educational Initiatives to Prevent Food Choking Injuries in Children: An Overview of the Current Approaches
by: Giulia Lorenzoni, et al.
Published: (2022)